Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE versus DURANEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE versus DURANEST.
BUPIVACAINE HYDROCHLORIDE vs DURANEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 mL for surgical anesthesia.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
None Documented
None Documented
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic